Avadim Holdings' Theraworx Protect Secures Innovative Technology Contract from Vizient

Avadim Holdings, Inc. has announced that its product, Theraworx Protect, has been awarded an Innovative Technology contract by Vizient, Inc., the largest provider-driven healthcare performance improvement company in the United States. This significant development could potentially transform infection control practices in healthcare settings across the country.

The contract was granted based on recommendations from hospital experts serving on Vizient's customer-led councils. These experts recognized Theraworx Protect's unique qualities and its potential to bring substantial improvements to the healthcare industry. The Innovative Technology Program at Vizient is designed to identify and promote products that can enhance clinical care, patient safety, healthcare worker safety, or improve business operations in healthcare organizations.

Keith Daniels, CEO of Avadim Health, expressed enthusiasm about the contract, stating, "We are very excited to have Theraworx Protect receive a Vizient Innovative Technology contract. Helping healthcare providers care for patients is important work, and we are eager to demonstrate how Theraworx Protect can help impact the delivery of care."

Theraworx Protect is marketed as an Advanced Hygiene and Barrier system that can serve as a non-inferior alternative to chlorhexidine gluconate (CHG) bathing in various healthcare settings. These include adult and pediatric ICUs, critical care units, pre-surgical patient care, and for patients with indwelling catheters. The product has gained trust among hospitals and healthcare settings as part of their infection control bundles for central line-associated bloodstream infections, catheter-associated urinary tract infections, and surgical site infections.

What sets Theraworx Protect apart is its low pH formulation that supports four critical systems: acidic pH, surfactant, preservative, and barrier systems. These components are crucial in maintaining proper skin function and integrity while creating an environment hostile to pathogens. A study published in the American Journal of Infection Control has shown Theraworx Protect to be a safe, non-inferior alternative to antiseptic products that often come with patient and usage limitations.

Kelly Flaharty, senior director of contract services at Vizient, highlighted the importance of the Innovative Technology Exchange, stating, "The Innovative Technology Exchange fosters a unique opportunity for healthcare providers to interact with products and services that have the potential to impact the healthcare industry and improve clinical care or business model of organizations."

Vizient's diverse customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute healthcare providers. With a portfolio representing more than $140 billion in annual purchasing volume, Vizient's endorsement of Theraworx Protect could significantly influence infection control practices across a wide range of healthcare settings.

The adoption of Theraworx Protect by Vizient member organizations could lead to improved patient outcomes, reduced healthcare-associated infections, and potentially lower healthcare costs. As healthcare providers continue to seek innovative solutions to combat infections and improve patient care, products like Theraworx Protect may play an increasingly important role in shaping the future of healthcare hygiene and infection control practices.